Between June 2000 and February 2007, all patients with diagnosis of locally advanced cervical cancer referred to the Division of Gynecologic Oncology of the University Campus Bio-Medico of Rome were eligible for this protocol. All enrolled patients received 3 cycles of platinum-based chemotherapy every 3 weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq. After neoadjuvant chemotherapy all patients with stable or progressive disease were excluded from the protocol, the others were submitted to classical radical hysterectomy, bilateral salpingo-oophorectomy and bilateral systematic pelvic lymphadenectomy and 4 cycles of adjuvant treatment with platinum based chemotherapy were executed.
Concerning intention to treat basis analysis, 5 year overall survival (OS) and disease-free survival (DFS) are 77 % and 61 % , respectively. The 5-year OS of patients with positive pelvic nodes and those with negative nodes metastases was respectively 60 % and 87 % . Concerning the according to protocol analysis, the 5-year OS and DFS are 81 % and 70 % respectively. The 5-year OS in patient with positive and negative lymph nodes is 75 % and 88 % respectively.
The adjuvant chemotherapy regimen after neoadjuvant chemotherapy and radical surgery represents a valid treatment for patients with locally advanced cervical cancer.